Patent intelligence · RU
RU 2203884
RETINOID COMPOUNDS (VARIANTS), COMPOSITION, METHOD FOR ASSAY OF RETINOID HORMONE ANTAGONISTS, METHOD OF TREATMENT AND INTERMEDIATE SUBSTANCES
RETINOID COMPOUNDS (VARIANTS), COMPOSITION, METHOD FOR ASSAY OF RETINOID HORMONE ANTAGONISTS, METHOD OF TREATMENT AND INTERMEDIATE SUBSTANCE…
Patent details — RU 2203884
- Jurisdiction
- RU
- Status
- expired
- Grant date
- May 10, 2003
- Expiration
- May 5, 2023
- Applicant
- ALLERGEN SEJLZ INK [US]
- CPC classes
- A61K 31/ 15 A I, A61K 31/ 37 A I, A61K 31/ 44 A I, A61K 31/ 47 A I
Quick answer
RU 2203884 (RETINOID COMPOUNDS (VARIANTS), COMPOSITION, METHOD FOR ASSAY OF RETINOID HORMONE ANTAGONISTS, METHOD OF TREATMENT AND INTERMEDIATE SUBSTANCES) is held by ALLERGEN SEJLZ INK [US]. Status: expired. Granted May 10, 2003. Expires May 5, 2023 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ALLERGEN SEJLZ INK [US]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 31/ 15 A I, A61K 31/ 37 A I, A61K 31/ 44 A I, A61K 31/ 47 A I, A61K 31/ 192 A I, A61K 31/ 215 A I
More from ALLERGEN SEJLZ INK [US]
Related pharmaceutical patents in our USPTO index.
-
CN 112638413
Oral immunotherapy unit dose dispensing systems and methods
granted -
WO 2015187736
FORMULATIONS PLACEBO ET UTILISATIONS DE CELLES-CI
granted -
US 2014356438
PERIPHERALLY ADMINISTERED VISCOUS FORMULATIONS
granted -
US 2014271721
PEANUT FORMULATIONS AND USES THEREOF
granted -
US 2014271836
MANUFACTURE OF PEANUT FORMULATIONS FOR ORAL DESENSITIZATION
granted -
US 2013209398
CONDITIONED CELL CULTURE MEDIUM COMPOSITIONS AND METHODS OF USE
granted -
CA 2849366
COMPOSITIONS ET PROCEDES POUR TRAITER LA PRESBYTIE, L'HYPERMETROPIE LEGERE ET L'ASTIGMATISME IRREGULIER
granted -
US 2012003230
SUSTAINED RELEASE DRUG DELIVERY SYSTEMS COMPRISING A WATER SOLUBLE THERAPEUTIC AGENT AND A RELEASE MODIFIER
granted
Frequently asked questions
What is US patent 2203884?
RU 2203884 (RETINOID COMPOUNDS (VARIANTS), COMPOSITION, METHOD FOR ASSAY OF RETINOID HORMONE ANTAGONISTS, METHOD OF TREATMENT AND INTERMEDIATE SUBSTANCES) is held by ALLERGEN SEJLZ INK [US]. Status: expired. Granted May 10, 2003. Expires May 5, 2023 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns RU 2203884?
ALLERGEN SEJLZ INK [US] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 24 pharmaceutical patents for this assignee.
When does RU 2203884 expire?
Our index shows an expiration date of May 5, 2023 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.